Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
16 10월 2023 - 7:07AM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced it will present updated Phase 1/2
trial data for bavdegalutamide (ARV-110) at the 2023 European
Society for Medical Oncology (ESMO) Annual Congress.
Bavdegalutamide is an investigational orally bioavailable PROTAC®
androgen receptor (AR) degrader and is being developed as a
potential treatment for men with metastatic castration-resistant
prostate cancer (mCRPC). This update will be presented during a
poster session at the annual congress being held from October
20-24, 2023, in Madrid, Spain.
Poster session details are as follows:
Date: Sunday, October 22, 2023Time: 12:00 – 1:00 p.m. CEST /
6:00 – 7:00 a.m. EDTPresentation Number: 1803PSpeaker: Daniel
Petrylak, M.D.
- Phase 1/2 study of bavdegalutamide, a PROTAC androgen receptor
(AR) degrader, in metastatic castration-resistant prostate cancer
(mCRPC): radiographic progression-free survival (rPFS) in patients
(pts) with AR ligand-binding domain (LBD) mutations.
For more information, visit the official ESMO Congress website
here.
Investor Call & Webcast DetailsArvinas will
host a conference and webcast call on Sunday, October 22 at 3 p.m.
CEST/9 a.m. ET to discuss the poster presentation. A live audio
webcast of the presentation and supporting material will be
available on the Events & Presentations section in
the Investors & Media section of the Company’s website. A
replay of the webcast will be archived on the Arvinas website
following the presentation.
About bavdegalutamide (ARV-110)Bavdegalutamide
(ARV-110) is an investigational orally bioavailable PROTAC® protein
degrader designed to selectively target and degrade the androgen
receptor (AR). Bavdegalutamide is being developed as a potential
treatment for men with mCRPC.
Bavdegalutamide has demonstrated activity in preclinical models
of AR mutation or overexpression, both potential mechanisms of
resistance to currently available AR-targeted therapies.
About ArvinasArvinas is a clinical-stage
biotechnology company dedicated to improving the lives of patients
suffering from debilitating and life-threatening diseases through
the discovery, development, and commercialization of therapies that
degrade disease-causing proteins. Arvinas uses its proprietary
PROTAC® Discovery Engine platform to engineer proteolysis targeting
chimeras, or PROTAC targeted protein degraders, that are designed
to harness the body’s own natural protein disposal system to
selectively and efficiently degrade and remove disease-causing
proteins. In addition to its robust preclinical pipeline of PROTAC
protein degraders against validated and “undruggable” targets, the
company has three investigational clinical-stage programs:
bavdegalutamide and ARV-766 for the treatment of men with
metastatic prostate cancer; and vepdegestrant (ARV-471) for the
treatment of patients with locally advanced or metastatic ER+/HER2-
breast cancer. For more information, visit www.arvinas.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995 that involve
substantial risks and uncertainties, including statements regarding
the potential advantages and therapeutic benefits of the company’s
investigational clinical stage programs. All statements, other than
statements of historical facts, contained in this press release are
forward-looking statements.
Arvinas may not actually achieve the plans, intentions or
expectations disclosed in its forward-looking statements, and you
should not place undue reliance on forward-looking statements.
Actual results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements we make as a result of various risks and uncertainties,
as discussed in the “Risk Factors” section of Arvinas’ Annual
Report of Form 10-K for the year ended December 31, 2022 and
subsequent other reports on file with the U.S. Securities and
Exchange Commission. The forward-looking statements contained in
this press release reflect Arvinas’ current views with respect to
future events, and the company assumes no obligation to update any
forward-looking statements except as required by applicable law.
These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this release.
Contacts
Investors:Jeff
Boyle347-247-5089Jeff.Boyle@arvinas.com
Media:Kirsten
Owens203-584-0307Kirsten.Owens@arvinas.com
Arvinas (NASDAQ:ARVN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Arvinas (NASDAQ:ARVN)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024